Silo Pharma FY2025 operating loss narrows 9% to $(4.28) million; net loss drops 3.8% to $(4.23) million

Reuters03-28
<a href="https://laohu8.com/S/SILO">Silo Pharma</a> FY2025 operating loss narrows 9% to $(4.28) million; net loss drops 3.8% to $(4.23) million
  • Silo Pharma published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025, reporting revenue of USD 72,102 and cost of revenue of USD 44,295.
  • Gross profit was USD 27,807, while operating loss from continuing operations narrowed 9% to USD 4.28 million on operating expenses of USD 4.31 million.
  • Net loss narrowed 3.8% to USD 4.23 million, and other income, net fell 83.1% to USD 52,964, driven mainly by lower interest and dividend income plus higher crypto-asset losses and impairment and higher interest expense.
  • Cash used in operating activities increased 21.6% to USD 4.66 million, while net cash provided by financing activities rose 49.9% to USD 4.86 million on net proceeds from sales of common stock and pre-funded warrants and proceeds from warrant exercises.
  • Management said cash and cash equivalents were USD 4.75 million at year-end and expects current cash, cash equivalents and short-term investments to be sufficient to meet obligations for at least 12 months from the filing date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silo Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-035576), on March 27, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment